

Form for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

S. No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction notified by the audit committee	Date of Audit Committee Meeting where the notification was approved	If case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to either party, inter-corporate deposits, advances or investments		Details of the loans, inter-corporate deposits, advances or investments				Notes						
	Name	PAN	Name	PAN							Relationship of the counterparty with the listed entity or its subsidiary	Opening balance	Closing balance	Value of indebtedness (only in case of loan/ advances or investments)	Details of other indebtedness	Cost	Tenure	Interest Rate (%)		Tenure	Secured/ unsecured	Purpose for which the funds will be utilized by the ultimate recipient of funds (if relevant)			
	Add	Update																							
1	Covid Pharma Limited		Chenging Carelle Pharmaceutical Co., Ltd		Follow subsidiary	Purchase of goods or services	207.30	NA			76.47	0.00	0.00												
2	Covid Pharma Limited		Fossil Pharma USA Inc.		Follow subsidiary	Any other transaction	100.00	NA			145.13	0.00	0.00												
3	Covid Pharma Limited		Fossil Pharma USA Inc.		Follow subsidiary	Any other transaction	4000.00	NA			2459.78	1483.43	438.44												
4	Covid Pharma Limited		Shree Carelle USA, Inc.		Follow subsidiary	Sale of goods or services	40.00	NA			102.14	0.00	0.00												
5	Covid Pharma Limited		Covid Pharma International Pvt. Ltd.		Wholly Owned Subsidiary	Sale of goods or services	2100.00	NA			1373.73	176.47	121.24												
6	Covid Pharma Limited		Covid Pharma International Pvt. Ltd.		Wholly Owned Subsidiary	Investment	6300.00	NA			520.85	0.00	0.00												
7	Covid Pharma Limited		Fosun Weibang (Group) Pharmaceutical Group CO., LTD.		Follow subsidiary	Purchase of goods or services	2100.00	NA			1056.53	-111.56	6.49												
8	Covid Pharma Limited		Shree Weibang Helios International Trade Co., Ltd.		Follow subsidiary	Sale of goods or services	100.00	NA			13.74	0.00	10.89												
9	Covid Pharma Limited		Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.		Follow subsidiary	Purchase of goods or services	35.00	NA			11.91	-15.43	-2.65												
10	Covid Pharma Limited		Huasheng Biopharmaceutical Co., Ltd.		Follow subsidiary	Purchase of goods or services	100.00	NA			36.26	0.00	0.00												
11	Covid Pharma Limited		Fossil Pharma S&P		Follow subsidiary	Sale of goods or services	40.00	NA			18.96	11.45	30.38												
12	Covid Pharma Limited		Fossil Pharma S&P		Follow subsidiary	Any other transaction	60.00	NA			7.44	0.00	0.00												
13	Covid Pharma Limited		Sinova S&S		Key management personnel	Reimbursement	211.28	NA			204.19	36.34	28.74												
14	Covid Pharma International Pvt. Ltd.		Sinova S&S		Key management personnel	Any other transaction	36.40	NA			36.40	0.00	0.00												
15	Covid Pharma Limited		Resh Shethar Mitra		Key management personnel	Reimbursement	66.90	NA			66.90	-5.14	6.88												
16	Covid Pharma Limited		Dhyanraj.com		Key management personnel	Reimbursement	60.50	NA			60.50	15.50	11.70												
17	Covid Pharma Limited		Srinivaswara Murthy Chavali		Director	Any other transaction	1.70	NA			1.70	0.00	0.00												
18	Covid Pharma Limited		Srinivaswara Murthy Chavali		Director	Any other transaction	2.30	NA			2.30	2.25	2.25												
19	Covid Pharma International Pvt. Ltd.		Srinivaswara Murthy Chavali		Director	Director Remuneration (wholly Owned Subsidiary)	1.60	NA			1.60	0.00	1.60												
20	Covid Pharma Limited		JLRB LITTELL		Key management personnel	Any other transaction	1.40	NA			1.40	0.00	0.00												
21	Covid Pharma Limited		JLRB LITTELL		Key management personnel	Any other transaction	1.50	NA			1.50	1.24	1.24												
22	Covid Pharma Limited		Fossil Capital Management		Key management personnel	Any other transaction	1.20	NA			1.20	0.00	0.00												
23	Covid Pharma Limited		Fossil Capital Management		Key management personnel	Any other transaction	1.50	NA			1.50	1.24	1.24												
24	Covid Pharma Limited		Kanadi KARAN		Key management personnel	Any other transaction	0.70	NA			0.70	0.00	0.00												
25	Covid Pharma Limited		Kanadi KARAN		Key management personnel	Any other transaction	10.00	NA			10.00	0.00	0.00												
26	Covid Pharma Limited		P. Suresh Kumar		Key management personnel	Reimbursement	18.90	NA			18.90	0.00	0.00												
Total value of transaction during the reporting period:												1480.89													

Notes:

- The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, are to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
- Loans made shall not be required to provide the disclosure with respect to related party transactions including loans, inter-corporate deposits, advances or investments made or given to listed banks.
- For companies with financial year ending March 31, the information has to be provided for its months ended September 30 and six months ended March 31.
- Companies with financial year ending in other months, the six months period shall apply accordingly.
- Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transaction of same type.
- However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, loan transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting of loan and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, unless one netting off.
- In case of a multi-year related party transaction.
- The aggregate value of all related party transactions as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
- The value of the related party transaction notified by the audit committee shall be disclosed in the column "Value of the related party transaction notified by the audit committee".
- The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
- "Cost" refers to the cost of borrowed funds for the listed entity. If Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable (different to all shareholders)/public shall also be reported.